Tacedinaline
| CAS No. | 112522-64-2 |
|---|---|
| MDL No. | MFCD00866266 |
| MF | C15H15N3O2 |
| MW | 269.30 |
| InChI Key | VAZAPHZUAVEOMC-UHFFFAOYSA-N |
Pricing & Availability
| Pack Size | Purity | Price | Availability | Action |
|---|---|---|---|---|
| - | - | On Request | On Request | |
| Custom synthesis and bulk supply options are available upon request. | ||||
Product Information
Tacedinaline is a benzamide formed by the formal condensation of the carboxy group of 4-acetamidobenzoic acid with one amino group of 1,2-phenylenediamine. It is an oral cytostatic drug with differential activity against leukemic cells and normal stem cells. Used in combination therapy for non-small cell lung, pancreatic, breast, and colorectal cancers. It functions as an EC 3.5.1.98 (histone deacetylase) inhibitor and antineoplastic agent. It belongs to acetamides, benzamides, substituted anilines, and is functionally related to 1,2-phenylenediamine.
| CAS No. | 112522-64-2 |
|---|---|
| Product Name | Tacedinaline |
Biological Targets
HDAC1·HDAC3·HDAC6·HDAC2·HDAC5·
Associated Conditions
multiple myeloma·lung cancer·pancreatic carcinoma
* The information provided here is compiled from public sources and is for reference only.
